PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment

PETMED EXPRESS INC

Q4 net sales $42.8M (down 15.6% YoY); FY net sales $179M (down 21.1%) on lower prescription sales.
Q4 net loss narrowed to $4.1M ($0.19/sh) from $11.6M; FY net loss widened to $57.3M ($2.74/sh) from $6.3M.
FY adjusted EBITDA -$15.4M (vs +$0.7M) due to $26.7M goodwill impairment and $4.5M severance/investigation.
Board evaluated unsolicited buyout proposals at $4.00-$4.25/sh but opted not to pursue; open to future offers.
Management cites sequential QoQ sales uptick, cost reductions, and B2B expansion (Rural King fulfillment deal).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PETMED EXPRESS INC reported fiscal year ended March 31, 2026 results: revenue $179.0 million, net income Net loss of $57.3 million, EPS $(2.74) per diluted share.

Period: fiscal year ended March 31, 2026
Revenue: $179.0 million
Net income: Net loss of $57.3 million
EPS: $(2.74) per diluted share
Result: reported results

Exact text from the filing

Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PETMED EXPRESS INC reported fourth quarter ended March 31, 2026 results: revenue $42.8 million, net income Net loss of $4.1 million, EPS $(0.19) per diluted share.

Period: fourth quarter ended March 31, 2026
Revenue: $42.8 million
Net income: Net loss of $4.1 million
EPS: $(0.19) per diluted share
Result: reported results

Exact text from the filing

Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%, primarily driven by a decline in prescription medication sales. • Net loss of $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share, for the prior year period.

View on SEC.gov

Browse all earnings releases →

PETMED EXPRESS INC filing history →

Source: SEC EDGAR

accession 0001040130-26-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.